The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38

2009 ◽  
Vol 125 (12) ◽  
pp. 2957-2969 ◽  
Author(s):  
Melissa J. LaBonte ◽  
Philipp C. Manegold ◽  
Peter M. Wilson ◽  
Will Fazzone ◽  
Stan G. Louie ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Active Metabolite ◽  
Kinase Inhibitor ◽  
Gastric Cancer Cells ◽  
Her 2

A new tyrosine kinase inhibitor K905-0266 inhibits proliferation and sphere formation of glioblastoma cancer cells

2020 ◽  
Vol 28 (9) ◽  
pp. 933-938
Author(s):  
Senthilkumar Kalimuthu ◽  
Prakash Gangadaran ◽  
Ji Min Oh ◽  
Ramya Lakshmi Rajendran ◽  
Ho Won Lee ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Kinase Inhibitor ◽  
Sphere Formation

scholarly journals Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer

2019 ◽  
Vol 27 (8) ◽  
pp. 871-877 ◽  
Author(s):  
Xinwen Wang ◽  
Fupeng Zhang ◽  
Xi Yang ◽  
Meiping Xue ◽  
Xiaoli Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Second Generation ◽  
Kinase Inhibitor ◽  
Lung Cancer Cells ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase ◽  
Secreted Phosphoprotein 1

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), afatinib, has been approved for treating EGFR mutant lung cancer patients, but the mechanism of acquired resistance to afatinib has not been well studied. In this study, we established afatinib acquired resistant cell lines. Gene array technology was used to screen changes in gene expression between afatinib-resistant lung cancer cells and parental cells. Our results showed that secreted phosphoprotein 1 (SPP1) was significantly increased in afatinib-resistant lung cancer cells. To study the effect of SPP1 on afatinib resistance, siSPP1 was used to knock down SSP1 in afatinib-resistant lung cancer cells. Then sensitivity to afatinib and invasive ability were studied. We found that knockdown of SPP1 increased sensitivity of lung cancer cells to afatinib and decrease the ability of invasion. Of clinical significance, we found that SSP1 was upregulated in lung cancer tissues compared with adjacent normal tissues, and low level of SSP1 was strongly associated with better overall survival. Our results suggest that SPP1 enhanced the second-generation EGFR TKI resistance in lung cancer, and inhibiting SPP1 might be a therapeutic target to overcome afatinib resistance.

Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer

2016 ◽  
Vol 372 (2) ◽  
pp. 187-191 ◽  
Author(s):  
Giandomenico Roviello ◽  
Andrea Ravelli ◽  
Karol Polom ◽  
Roberto Petrioli ◽  
Luigi Marano ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Receptor Tyrosine Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document